SI Results

Intracellular bioavailability (Fic) of AKT1 inhibitors
To verify our findings with the PKIS, we selected an additional cluster of compounds (n=5) from this set. These compounds were initially developed as AKT1 inhibitors, an intracellular target involved in the cell cycle (1) . Despite all of these molecules being available in the cell interior (Fic >1; Table S2 ), only one (GSK1007102B) displayed sub-micromolar cellular potency (average pGI50 in NCI-60 panel of 6.7), making this the only class 1 compound of this series. A closer inspection of the biochemical potencies of the compounds showed that GSK1007102B was not only a stronger inhibitor of AKT1, but also more promiscuous (Dataset S2). Despite being able to reach intracellular targets, the other compounds in this series remained in class 3 owing to their lower biochemical potency.
Modulation of angiogenesis by the published kinase inhibitor set is affected by intracellular bioavailability (Fic)
PKIS compounds were screened for their capacity to modulate angiogenesis in primary human umbilical endothelial cells (HUVECs) (2) . The cellular outcome of this screen was the total tubule length normalized according to the B-score method, as described elsewhere (2) . A value of B-score ≤-1.5 is generally considered active. We compared Fic with the cellular outcome of this screen (Bscore) ( Figure S8a) . As with the cell growth inhibition data, there was a correlation, albeit weaker, between Fic and modulation of angiogenesis (rS = 0.42). Most of the compounds belonged to classes 1 (20%) and 4 (45%) ( Figure S8b ). Only three of the seven compounds in class 2 (GW305178X, GW589933X, GW779439X) appeared to be true class 2 compounds, as the other compounds only marginally belonged to this class (Fic >0.9). These three compounds had similar kinase inhibition profiles that can be related to particularly strong antiangiogenic activity (e.g., KDR inhibition) (2) . The high number of class 3 compounds (20%) was probably related to compound selection bias, since cytostatic properties (the cellular response for which compounds were initially selected) are not necessarily correlated with antiangiogenic effects (2). 
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